IGXT - IntelGenx Technologies Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2248
+0.0148 (+7.05%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.2100
Open0.2100
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2100 - 0.2250
52 Week Range0.1200 - 0.7000
Volume228,534
Avg. Volume545,634
Market Cap24.786M
Beta (5Y Monthly)1.48
PE Ratio (TTM)N/A
EPS (TTM)-0.1120
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    IntelGenx Announces Intention to Issue Shares in Payment of Principal on Outstanding Debentures, and Meeting of Debentureholders

    Under the terms of the trust indenture governing the Debentures (the “Indenture”), the Corporation has the option to satisfy its obligation to repay all or any portion of the principal amount of the Debentures outstanding by issuing and delivering Common Shares at a deemed price of 95% of the current market price (as defined in the Indenture) at the maturity date, subject to customary conditions set forth in the Indenture. The issuance of the Common Shares in repayment of the principal of the Debentures is subject to the acceptance by the TSX Venture Exchange (the “TSX-V”).

  • GlobeNewswire

    IntelGenx Confirms Type A Meeting with the FDA Regarding RIZAPORT® VersaFilm®

    SAINT LAURENT, Quebec, May 27, 2020 -- IntelGenx Corp. (TSX-V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that the U.S. Food & Drug Administration.

  • IntelGenx (IGXT) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    IntelGenx (IGXT) Reports Q1 Loss, Tops Revenue Estimates

    IntelGenx (IGXT) delivered earnings and revenue surprises of -50.00% and 102.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    IntelGenx Reports First Quarter 2020 Financial Results

    IntelGenx Technologies Corp. (TSX V:IGX)(IGXT) (the "Company" or "IntelGenx") today reported financial results for the first quarter ended March 31, 2020. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise. Announced a performance improvement program focused on generating near-term revenue, preserving the Company’s resources, extending its cash runway and accelerating the launch of RIZAPORT® in Spain.

  • GlobeNewswire

    IntelGenx Announces Intention to Amend Convertible Debentures

    The proposed amendments remain subject to approval of the TSX Venture Exchange and the holders of not less than 66 2/3% of the outstanding principal amount of the Debentures. IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended.

  • GlobeNewswire

    IntelGenx to Report First Quarter 2020 Financial Results on May 14, 2020 – Conference Call to Follow

    SAINT LAURENT, Quebec, May 08, 2020 -- IntelGenx Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its first.

  • Will IntelGenx (IGXT) Report Negative Q1 Earnings? What You Should Know
    Zacks

    Will IntelGenx (IGXT) Report Negative Q1 Earnings? What You Should Know

    IntelGenx (IGXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    IntelGenx Provides Status Update on Cannabis Micro-Processing License Application

    In response to investor and media inquiries, IntelGenx Technologies Corp. (TSX V:IGX)(IGXT) (the "Company" or "IntelGenx") provided an update regarding its micro-processing license application for its Montreal, Quebec facility that is currently being reviewed by Health Canada, in accordance with the Cannabis Act and Cannabis Regulations. “Based on recent conversations with Health Canada’s Controlled Substances and Cannabis Branch, which is reviewing our application, we were expecting to receive our micro-processing license sometime in April,” said Dr. Horst G. Zerbe, CEO of IntelGenx. “Health Canada has  continued to review applications for new cannabis licenses and security-clearance applications during the COVID-19 pandemic, however, as its staff are operating remotely with a limited ability to perform certain functions, we have to accept the possibility of a delay.”

  • GlobeNewswire

    IntelGenx Changes 2020 Annual Meeting of Stockholders to a Virtual-Only Format

    IntelGenx Technologies Corp. (TSX V:IGX)(IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that, due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic, and to support the health and well-being of the Company’s directors, employees and stockholders, the location of the Company’s 2020 Annual Meeting of Stockholders (including any adjournments or postponements, the “Annual Meeting”) has been changed to a virtual-only meeting format. Stockholders will not be able to attend the Annual Meeting in person, but instead will be able to attend virtually as noted below. As described in the proxy materials for the Annual Meeting that were previously distributed, stockholders are entitled to participate in the Annual Meeting if they were a stockholder of the Company as of the close of business on March 16, 2020, the record date, or hold a legal proxy for the Annual Meeting provided by the stockholder’s bank, broker, or nominee.

  • GlobeNewswire

    IntelGenx Announces Adjusted VersaFilm® Business Strategy, Next Steps for RIZAPORT® VersaFilm® Program

    IntelGenx Technologies Corp. (TSX V:IGX)(IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced various initiatives aimed at helping the Company address, and satisfactorily respond to, the Complete Response Letter (“CRL”) that it recently received from the U.S. Food and Drug Administration (“FDA”) regarding its resubmitted 505(b)(2) New Drug Application for RIZAPORT® VersaFilm®, as well as maintain IntelGenx’s financial stability in light of the current market environment and the challenges posed by the global COVID-19 pandemic. While IntelGenx’s business development strategy will continue to focus on partnering its current product pipeline, which includes 10 pharmaceutical oral film product candidates, and pursuing potential oral thin film manufacturing opportunities, in light of recent unforeseeable developments, the Company will also accelerate its focus to pursue short-term revenue generating opportunities by expanding its pipeline to include additional products for which there is not an FDA or Health Canada (“HC”) approval requirement.

  • GlobeNewswire

    IntelGenx Receives Complete Response Letter from FDA for RIZAPORT® NDA

    IntelGenx Technologies Corp. (TSX V:IGX)(IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that it has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its resubmitted 505(b)(2) New Drug Application (“NDA”) for RIZAPORT® VersaFilm® for the treatment of acute migraines. The CRL states that the FDA cannot approve the application in its present form. “Obviously, we are surprised and disappointed,” said Dr. Horst G. Zerbe, CEO of IntelGenx.

  • ACCESSWIRE

    IntelGenx Technologies Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 27, 2020 / IntelGenx Technologies Corp. (OTCMKTS:IGXT) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 27, 2020 ...

  • Benzinga

    Recap: Intelgenx Technologies Q4 Earnings

    Shares of Intelgenx Technologies (OTC:IGXT) remained unaffected at $0.26 after the company reported Q4 results.Quarterly Results Earnings per share were unchanged 0.00% year over year to ($0.03), which were in line with the estimate of ($0.03).Revenue of $68,000 less by 89.54% year over year, which beat the estimate of $60,000.Guidance Intelgenx Technologies hasn't issued any earnings guidance for the time being.Intelgenx Technologies hasn't issued any revenue guidance for the time being.Conference Call Details Date: Nov 07, 2019View more earnings on IGXTTime: 04:03 PM ETWebcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fpro.benzinga.com%2Fdashboard%2F&eventid=2080118&sessionid=1&key=7B713FDAD8E9001FC5B1F48BFCB73032®Tag=&sourcepage=registerPrice Action 52-week high: $0.3052-week low: $0.24Price action over last quarter: down 57.72%Company Description Intelgenx Technologies Corp is an oral drug delivery company. The company is focused on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilmTM technology platform. Intelegenx focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. Intelegenx offers its partners a comprehensive portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, tech transfer and manufacturing scale-up, and commercial manufacturing.See more from Benzinga * Recap: LiqTech International Q4 Earnings * Recap: Titan Machinery Q4 Earnings * Movado Group: Q4 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    IntelGenx Reports Fourth Quarter and Full-Year 2019 Financial Results

    IntelGenx Technologies Corp. (TSX V:IGX)(IGXT) (the "Company" or "IntelGenx") today reported financial results for the fourth quarter and twelve-month periods ended December 31, 2019. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise.

  • GlobeNewswire

    INTELGENX TO REPORT FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS ON MARCH 26; CONFERENCE CALL TO FOLLOW ON MARCH 27

    SAINT LAURENT, Quebec, March 23, 2020 -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its.

  • GlobeNewswire

    IntelGenx Completes C$8.2 Million Equity Offering

    IntelGenx Technologies Corp. (IGX.V) (IGXT) (the “Company” or “IntelGenx”) is pleased to announce that it has closed its offering (the “Offering”) of 16,317,000 units (the “Units”) at a price of C$0.50 per Unit (the “Offering Price”) for gross proceeds of C$8,158,500. Each Unit consists of one share of common stock (the “Offered Shares”) and one warrant (a “Warrant”) entitling the holder to purchase one share of common stock of the Company at an exercise price of C$0.75 per share (a “Warrant Share”).

  • GlobeNewswire

    IntelGenx Announces Pricing of Equity Offering

    IntelGenx Technologies Corp. (IGX.V) (IGXT) (the “Company” or “IntelGenx”) announced today the pricing of an agency offering (the “Offering”) of up to 20,000,000 units, subject to a minimum offering of 10,000,000 units (the “Units”), for gross proceeds of between $5,000,000 and $10,000,000, assuming no exercise of the over-allotment option granted to the Agent (as defined below), at a price of $0.50 per Unit. Each Unit will consist of one share (each, an “Offered Share”) of common stock of the Company (“Common Stock”) and one warrant (each, a “Warrant”) to purchase one share of Common Stock at an exercise price of $0.75 per share (a “Warrant Share”). The Offering is being conducted on a commercially reasonable best efforts basis by Echelon Wealth Partners Inc. (the “Agent”) in the provinces of British Columbia, Alberta, Manitoba and Ontario.

  • GlobeNewswire

    IntelGenx Receives Health Canada Authorization to Proceed with New Amendment for Montelukast VersaFilm® Phase 2a Trial

    - Ongoing BUENA Trial to Continue at Increased Daily Dose - SAINT LAURENT, Quebec, Jan. 15, 2020 -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in.

  • GlobeNewswire

    IntelGenx Provides Commercial Update on its Two Lead VersaFilm® Product Candidates, Cannabis-Infused Oral Film and RIZAPORT®

    “Because we believe this is an exciting product that will meet, if not exceed, consumer expectations, we think that we're well positioned to become a significant player in this expanding market as new product formats come online,” commented Dr. Horst G. Zerbe, CEO of IntelGenx.

  • GlobeNewswire

    IntelGenx Enters Animal Health Market by Signing Feasibility Agreement for VetaFilm™ Platform

    SAINT LAURENT, Quebec, Jan. 09, 2020 -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”) a leader in pharmaceutical films, today announced that it has entered into a.

  • GlobeNewswire

    IntelGenx Files Preliminary Short Form Prospectus in Connection With a Proposed Offering of Units

    IntelGenx Technologies Corp. (IGX.V) (IGXT) (the “Company” or “IntelGenx”) is pleased to announce that it has filed a preliminary short form prospectus (the “Prospectus”) with respect to an offering (the “Offering”) of units (“Units”) for a minimum of Cdn$4,000,000 and a maximum of Cdn$10,000,000 aggregate gross proceeds. Each Unit will consist of one share (an “Offered Share”) of the common stock of the Company (“Common Stock”) and one half of one common stock purchase warrant (each whole common stock purchase warrant, a “Warrant”).

  • GlobeNewswire

    IntelGenx Announces Issuance of Shares in Payment of Interest on Outstanding Debentures

    IntelGenx Technologies Corp. (IGX.V) (IGXT) (the “Company” or “IntelGenx”) announces that it intends to issue 415,178 common shares of the Corporation (the “Common Shares”) at a deemed price of CAD $0.73 per Common Share in payment of an aggregate of $303,080 in interest owing on the Corporation’s 8.00% convertible unsecured subordinated debentures due June 30, 2020 (the “Debentures”). Under the terms of the trust indenture governing the Debentures (the “Indenture”), the Corporation has the option to pay the semi-annual interest on the Debentures in either cash or Common Shares, subject to customary conditions set forth in the Indenture.

  • GlobeNewswire

    IntelGenx to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference

    SAINT LAURENT, Quebec, Dec. 03, 2019 -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced.

  • GlobeNewswire

    IntelGenx Reports Third Quarter 2019 Financial Results

    SAINT LAURENT, Quebec, Nov. 07, 2019 -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today reported.

  • GlobeNewswire

    IntelGenx to Report Third Quarter 2019 Financial Results on November 7, 2019 – Conference Call to Follow

    SAINT LAURENT, Quebec, Nov. 01, 2019 -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced.